The one named permanent A list celebrity is going to get everyone hooked on the shot while she has cornered the market on the pill that is twice as effective and will be sold to the elite so they can look down on the people who have to get the shot.
Oprah
Shot: Ozempic
Novo Nordisk
Novo Nordisk’s CEO is optimistic about their new weight loss pill, amycretin, potentially outperforming current treatments for obesity.
The pill showed promising results in early trials, offering a more convenient alternative to injections like Wegovy.
Despite the positive outlook, amycretin won’t hit the market soon, with trials expected to continue until 2026.
The company aims to address different patient preferences with amycretin’s unique approach, targeting both gut and pancreas hormones.
While the news boosted Novo Nordisk’s stock initially, it dipped slightly afterward.
